A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s) | MicrobiomeTrials
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-03-17Est. Completion: 2026-10-19
Enrollment target: 30 participants
Locations
Visterra Investigational Site, Sofia, Bulgaria
Visterra Investigational Site, Chisinau, Moldova
Visterra Investigational Site, Bucharest, Romania
Visterra Investigational Site, Cluj-Napoca, Romania
Visterra Investigational Site, Barcelona, Spain
Visterra Investigational Site, Granada, Spain
Other microbiome trials you might be interested in